P. Muus

Stem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study (2007)

Labar, B., Suciu, S., Muus, P., Willemze, R., Marie, J.P., Fillet, Georges, ...

Non-infusional vs intravenous consolidation chemotherapy in eldery patients with acute myeloid leukemia : final results of th EORTC-GIMAMA AML-13 randomized phase III trial (2006)

Jehn, U., Suciu, S., Thomas, X., Lefrère, F., Muus, P., Berneman, Zwi, ...

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921) (2003)

Suciu, S, Labar, B, Belhabri, A, Aul, C, ...

This report used the framework of a large European study to investigate the outcome of patients with and without an HLA-identical sibling donor on an intention-to-treat basis. After a common...

Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors (2002)

Muus, P, Suciu, S, Koller, C, Labar, B, ...

Comparisons of the effectiveness of chemotherapy and transplantation in AML in first complete remission (CR) have focused almost exclusively on patients with de novo disease. Here we used Cox...

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS (2001)

Suciu, S, Labar, B, Archimbaud, E, Aul, C, ...

This study investigated the feasibility of allogeneic (alloSCT) and autologous stem cell transplantation (ASCT) as postconsolidation therapy for patients with myelodysplastic syndromes (MDSs) or...

Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and Idarubicin (AIDA) therapy (1997)

Coco, F. Lo, Biondi, A., Pellici, P.G., Muus, P., Willemze, R., Jehn, U., ...

Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells (1997)

Landegent, J.E., Willemze, R., Beverstock, G.C., Wessels, J.M.C., Muus, P., Bolk, M.J.W., ...

All-Trans retinoic acid-induced thrombocytosis in a patient with acute promyelocytic leukaemia (1997)

Feremans, W., Mandelli, F., Muus, P., Meyer, S., Capel, P., Crenier, L., ...

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial (1997)

Willemze, R., Dardenne, M., Resegotti, L., Thaler, J., Peetermans, M., Stryckmans, P., ...

Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the research and treatment of cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON) (1997)

Zittoun, R., Dardenne, M., Sonneveld, P., Muus, P., Jehn, U., Schouten, H.C., ...

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893) (1997)

Zittoun, R., Dardenne, M., Jaksic, B., Labar, B., Jehn, U., Dohner, H., ...

Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial (1996)

Zittoun, R., Vegna, M.L., Solbu, G., Dardenne, M., Petti, M.C., Muus, P., ...

Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (06901) of the EORTC Leukemia Cooperative Group (1996)

Muus, P., Solbu, G., Dardenne, M., Hayat, M., Kurstjens, R., Ribeiro, M., ...

Immigration - mismatches in labor, housing and space - the effects of immigration of several nationalities with regard to the Netherlands (1995)

Musterd, S., Muus, P.

In the Netherlands, the sharp recent increase of the number of refugee immigrants (asylum seekers) runs parallel to increased numbers of immigrants of other types, Therefore, at least five types of...

Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration : a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG) (1995)

Muus, P., Zwierzina, H., Solbu, G., Dardenne, M., Zittoun, R., Selleslag, S., ...

1-beta-D-arabinofuranosylcytosine (Ara-C) enhances mitochondrial activities in human leukaemic cells.

Muus, P., De Vries, H., Pennings, A., Holtrop, M., Haanen, C.

1-beta-D-Arabinofuranosylcytosine (Ara-C) at a concentration which inhibits nuclear-DNA reduplication (0.05 microM), enhances mitochondrial activities like respiration, in cell of a human leukaemic...